Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.

Cancer · 2016 · PMC5071708 · PMID 26998677

Europe PMC DOI

hedged sentence

0.0655

closest p · 1.3× alpha

0.0655

boldest claim

The sentences

of borderline significanceP = .0655so close (0.05 < p ≤ 0.1)

These differences were statistically significant in patients with CML‐AP ( P = .0003) and of borderline significance ( P = .0655) in patients with presumably more advanced CML‐CP who received dasatinib as second‐line or third‐line treatment.

also in 1,677 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.